Akebia Therapeutics, Inc. (AKBA) vs Twist Bioscience Corporation (TWST)
The same free fields, in the same order, for both companies, so a figure on one line can be read straight across.
This page states measurements and nothing else. It does not rank the two companies, name one of them, or draw a conclusion from the figures.
Data as of Oct 27, 2026, for both companies.
The figures, field by field
A dash means the snapshot carries no figure for that company on that line. A line is dropped only when neither company has it, so a dash beside a figure is a fact about coverage, not about either company.
| AKBA | TWST | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Size band | SMALL | MID |
| Listing | Nasdaq CM | Nasdaq GS |
| Country | United States | United States |
| Theme | rare-disease | life-science-tools |
| Price and returns | ||
| Last close | $0.64 | $145.25 |
| Return · 1 week | −5.32% | +3.92% |
| Return · 1 month | −27.91% | −19.13% |
| Return · 3 months | −49.31% | +64.03% |
| Return · year to date | −58.46% | +348.44% |
| Return · 1 year | −79.69% | +324.96% |
| Distance from the 52-week highThe last close measured against the highest close of the past 52 weeks. | −79.88% | −33.89% |
| 52-week high | $3.20 | $219.71 |
| 52-week low | $0.54 | $23.30 |
| Size and turnover | ||
| Market value · USDConverted to US dollars, so two companies listed in different currencies sit under one heading. | $178.40M | $9.63B |
| Turnover · median day, USDThe median value traded in a session over the past 50 sessions. | $4.77M | $302.09M |
| Employees | 194 | 979 |
| Valuation | ||
| Price to earnings · trailing | n/a (negative earnings) | n/a (negative earnings) |
| Price to earnings · forward | n/a (negative forward earnings) | n/a (negative forward earnings) |
| Price to sales | 1.01× | 20.38× |
| Price to book | 8.71× | 18.67× |
| Enterprise value to EBITDA | n/a (negative EBITDA) | n/a (negative EBITDA) |
| Enterprise value to revenue | 1.30× | 19.14× |
| Earnings per share · trailing | -0.12 | -2.23 |
| Profitability | ||
| Gross margin | 79.63% | 51.97% |
| Operating margin | −5.46% | −30.65% |
| Profit margin | −13.54% | −31.66% |
| Return on equity | −109.38% | −29.59% |
| Return on assets | −1.05% | −13.09% |
| Growth | ||
| Revenue growth | −21.40% | +23.20% |
| Balance sheet and payout | ||
| Debt / equity (%) | 796.18 | 24.36 |
| Current ratio | 1.43 | 2.67 |
| Dividend yield | 0.00% | 0.00% |
| Trend and volatility | ||
| RSI · 14 | 35.08 | 38.20 |
| ADX · 14 | 33.65 | 25.91 |
| 50-day average | $0.86 | $147.91 |
| 200-day average | $1.16 | $83.26 |
| Average true range · share of priceAverage true range over 14 sessions, stated as a share of the last close, so it can be read across two share prices. | 8.40% | 11.43% |
The full AKBA analysis
Everything this table leaves out for Akebia Therapeutics, Inc.: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the AKBA argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full AKBA analysisThe full TWST analysis
Everything this table leaves out for Twist Bioscience Corporation: the plain-language summary and key points, the accumulation read, signal history, full fundamentals, market context, and the case each side of the TWST argument makes.
$9.90 per stock, one time, 30 days of access.
Open the full TWST analysis